Search

Your search keyword '"Sobue, G."' showing total 40 results

Search Constraints

Start Over You searched for: Author "Sobue, G." Remove constraint Author: "Sobue, G." Topic receptors, androgen Remove constraint Topic: receptors, androgen
40 results on '"Sobue, G."'

Search Results

1. Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy.

2. Disease Affects Bdnf Expression in Synaptic and Extrasynaptic Regions of Skeletal Muscle of Three SBMA Mouse Models.

3. Pre-clinical symptoms of SBMA may not be androgen-dependent: implications from two SBMA mouse models.

4. A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy.

5. MiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy.

6. Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy.

7. Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors.

8. Paeoniflorin eliminates a mutant AR via NF-YA-dependent proteolysis in spinal and bulbar muscular atrophy.

9. p62/SQSTM1 differentially removes the toxic mutant androgen receptor via autophagy and inclusion formation in a spinal and bulbar muscular atrophy mouse model.

10. Androgen receptor inclusions acquire GRP78/BiP to ameliorate androgen-induced protein misfolding stress in embryonic stem cells.

11. Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract.

12. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy.

13. Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy.

14. [Molecular-targeted therapy for spinal and bulbar muscular atrophy (SBMA)].

15. Clinical features and molecular mechanisms of spinal and bulbar muscular atrophy (SBMA).

16. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse.

17. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model.

18. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor.

19. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker.

20. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients.

21. Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.

22. Hsp105alpha suppresses the aggregation of truncated androgen receptor with expanded CAG repeats and cell toxicity.

23. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein.

24. Transgenic mouse models of spinal and bulbar muscular atrophy (SBMA).

25. Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death.

26. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract.

27. Tissue-specific somatic mosaicism in spinal and bulbar muscular atrophy is dependent on CAG-repeat length and androgen receptor--gene expression level.

28. [Transcriptional regulation and subcellular localization of mutant androgen receptor in spinal and bulbar muscular atrophy].

29. [Somatic mosaicism of expanded CAG trinucleotide repeat in spinal and bulbar muscular atrophy (SBMA)].

30. [In vitro aggregation and cellular toxicity of mutant androgen receptor protein in spinal and bulbar muscular atrophy].

31. Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular atrophy in a polyglutamine repeat length-dependent manner.

32. Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy.

33. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy.

34. X-linked recessive bulbospinal neuronopathy: clinical phenotypes and CAG repeat size in androgen receptor gene.

35. Androgen receptor mRNA with increased size of tandem CAG repeat is widely expressed in the neural and nonneural tissues of X-linked recessive bulbospinal neuronopathy.

36. Aberrant androgen action and increased size of tandem CAG repeat in androgen receptor gene in X-linked recessive bulbospinal neuronopathy.

37. Subclinical phenotypic expressions in heterozygous females of X-linked recessive bulbospinal neuronopathy.

38. Very late onset X-linked recessive bulbospinal neuronopathy: mild clinical features and a mild increase in the size of tandem CAG repeat in androgen receptor gene.

39. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene.

40. [DNA diagnosis of X-linked recessive bulbospinal muscular atrophy by androgen receptor gene mutations].

Catalog

Books, media, physical & digital resources